

13 - References

References

578 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 References

1. Colom F, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. *Arch Gen Psychiatry* 2003; 60:402–407.
2. Young RC, et al. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 1978; 133:429–435.
3. Gracious BL, et al. Discriminative validity of a parent version of the Young Mania Rating Scale. *J Am Acad Child Adolesc Psychiatry* 2002; 41:1350–1359.
4. Poznanski EO, et al. Preliminary studies of the reliability and validity of the children's depression rating scale. *J Am Acad Child Psychiatry* 1984; 23:191–197.
5. Spearing MK, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. *Psychiatry Res* 1997; 73:159–171.
6. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical Guidance [CG185]. 2014 (last updated December 2023); <https://www.nice.org.uk/guidance/cg185>.
7. Correll CU, et al. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. *Bipolar Disord* 2010; 12:116–141.
8. Duffy A, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. *J Clin Psychiatry* 2002; 63:1171–1178.
9. Geddes JR, et al. Treatment of bipolar disorder. *Lancet* 2013; 381:1672–1682.
10. Diaz-Caneja CM, et al. Practitioner review: long-term pharmacological treatment of pediatric bipolar disorder. *J Child Psychol Psychiatry* 2014; 55:959–980.
11. Pacchiarotti I, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *Am J Psychiatry* 2013; 170:1249–1262.
12. DelBello MP, et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 2017; 56:1015–1025.
13. Singh MK, et al. Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2020; 30:590–598.
14. DelBello MP, et al. Tolerability, safety, and effectiveness of two years treatment with lurasidone in children and adolescents with bipolar depression. *J Am Acad Child Adolesc Psychiatry* 2021; 31:494–503.

15. Goldsmith M, et al. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? *Paediatr Drugs* 2011; 13:225-243.
16. Dickstein DP, et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. *J Child Adolesc Psychopharmacol* 2009; 19:61-73.
17. Vidal-Ribas P, et al. The status of irritability in psychiatry: a conceptual and quantitative review. *J Am Acad Child Adolesc Psychiatry* 2016; 55:556-570.
18. Miklowitz DJ. Evidence-based family interventions for adolescents and young adults with bipolar disorder. *J Clin Psychiatry* 2016; 77 Suppl E1:e5.
19. Wozniak J, et al. A randomized, double-blind, controlled clinical trial of omega-3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5-12. *Psychopharmacol Bull* 2022; 52:31-51.
20. Riccobene T, et al. Pharmacokinetics, safety, and tolerability of cariprazine in pediatric patients with bipolar I disorder or schizophrenia. *J Child Adolesc Psychopharmacol* 2022; 32:434-443.
21. Wall CA, et al. Magnetic resonance imaging-guided, open-label, high-frequency repetitive transcranial magnetic stimulation for adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2016; 26:582-589.
22. Pathak V, et al. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of right prefrontal cortex in adolescent mania: a randomized sham-controlled study. *Clin Psychopharmacol Neurosci* 2015; 13:245-249.
23. Moghaddam HS, et al. Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial. *Int Clin Psychopharmacol* 2020; 35:81--88.
24. Grant B, et al. Using lithium in children and adolescents with bipolar disorder: efficacy, tolerability, and practical considerations. *Paediatr Drugs* 2018; 20:303-314.
25. Geller B, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. *J Am Acad Child Adolesc Psychiatry* 1998; 37:171-178.
26. Kafantaris V, et al. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. *J Am Acad Child Adolesc Psychiatry* 2004; 43:984-993.
27. Findling RL, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. *Pediatrics* 2015; 136:885-894.
28. Findling RL, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2005; 44:409--417.
29. Duffy A, et al. Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-IGSLi joint task force on lithium treatment. *Bipolar Disord* 2018; 20:583-593.
30. Patino LR, et al. A randomized, double-blind, controlled trial of lithium versus quetiapine for the treatment of acute mania in youth with early course bipolar disorder. *J Child Adolesc Psychopharmacol* 2021; 31:485-493.
31. Findling RL, et al. Lithium for the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled discontinuation study. *J Am Acad Child Adolesc Psychiatry* 2019; 58:287-296.e284.

Wagner KD, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 2009; 48:519-532. 34. Wagner KD, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. *Am J Psychiatry* 2006; 163:1179-1186. 35. Tohen M, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. *Am J Psychiatry* 2007; 164:1547-1556. 36. DelBello MP, et al. A double-blind placebo-controlled pilot study of topiramate in manic adolescents treated with olanzapine. *J Child Adolesc Psychopharmacol* 2023; 33:126-133. 37. Haas M, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. *Bipolar Disord* 2009; 11:687-700. 38. Geller B, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. *Arch Gen Psychiatry* 2012; 69:515-528. 39. Walkup JT, et al. Treatment of early-age mania: outcomes for partial and nonresponders to initial treatment. *J Am Acad Child Adolesc Psychiatry* 2015; 54:1008-1019. 40. Kowatch RA, et al. Placebo-controlled trial of valproic acid versus risperidone in children 3-7 years of age with bipolar I disorder. *J Child Adolesc Psychopharmacol* 2015; 25:306-313. 41. Pathak S, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2013; 74:e100-e109. 42. Delbello MP, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. *J Am Acad Child Adolesc Psychiatry* 2002; 41:1216-1223. 43. Delbello MP, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. *J Am Acad Child Adolesc Psychiatry* 2006; 45:305-313. 44. Findling RL, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2009; 70:1441-1451. 45. Findling RL, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. *Bipolar Disord* 2013; 15:138-149. 46. Findling RL, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. *J Child Adolesc Psychopharmacol* 2013; 23:531-544. 47. Findling RL, et al. Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-controlled replication study. *J Child Adolesc Psychopharmacol* 2022; 32:143-152. 48. Findling RL, et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. *J Am Acad Child Adolesc Psychiatry* 2015; 54:1032-1041. 49. Detke HC, et al. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2015; 54:217-224. 50. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry* 2014; 171:160-168. 51. Suppes T, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. *J Psychiatr Res* 2016; 78:86-93. 52. Suppes T, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry* 2016; 173:400-407. 53. Goldman R, et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. *J Child Adolesc Psychopharmacol* 2017; 27:516-525. 54. Solmi M, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry* 2020; 19:214-232. 55. Delbello MP, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. *Bipolar Disord* 2009; 11:483--

493. 56. Findling RL, et al. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2014; 24:325–335. 57. Suttajit S, et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. *Drug Des Devel Ther* 2014; 8:827–838. 58. Bridge JA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta- analysis of randomized controlled trials. *JAMA* 2007; 297:1683--1696. 59. Calabrese JR, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. *Bipolar Disord* 2008; 10:323–333. 60. Findling RL, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. *J Am Acad Child Adolesc Psychiatry* 2015; 54:1020–1031.e1023.

Revision #1

Created 2026-01-04 20:16:33 UTC by Omar Ayman

Updated 2026-01-04 20:16:33 UTC by Omar Ayman